Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07936942

Quality of Life and Uremic Toxins in HDx

Conditions: End Stage Kidney Disease (ESKD)

Sex: All
Healthy volunteers: No
Phase: NA
Enrollment: 23
Sponsor: Mackay Memorial Hospital

Location: MacKay Memorial Hospital Taipei

Summary

Expanded hemodialysis (HDx) is a dialysis treatment designed to improve the removal of certain waste products from the blood. However, its effects on health-related quality of life and blood levels of uremic toxins in patients receiving long-term hemodialysis remain uncertain. This study aimed to evaluate changes in quality of life and uremic toxin levels after switching from conventional hemodialysis to HDx. Patients who had been receiving maintenance hemodialysis for at least 10 years underwent HDx for three months. Quality of life and blood levels of selected uremic toxins were assessed before and after the treatment period. The study aimed to determine whether switching to HDx was associated with changes in patients' quality of life and uremic toxin profiles.

Eligibility Criteria

Inclusion Criteria: * Adults aged 18 years or older. * Patients receiving maintenance hemodialysis three times weekly for at least 10 years. * Ability to provide written informed consent. Exclusion Criteria: * Active malignancy. * Other major organ failure. * History of major surgery within the preceding 3 months.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07936942). StuddyBuddy aggregates publicly available trial information.